-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5

Benzinga·07/30/2026 19:05:03
Listen to the news
BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $15 to $5.